Treatment | N | p[A]50 | Induction | Enhancement of FP-Induced Response |
---|---|---|---|---|
M | Fold | Fold | ||
FP (100 nM) | 8 | — | 11.8 ± 0.7 | 1.0 |
+ Cilomilast | 8 | −5.48 ± 0.98 | 23.7 ± 3.3* | 2.0 |
+ Formoterol | 8 | −10.41 ± 0.08 | 32.2 ± 1.3*,† | 2.7 |
FP (100 nM) | 7 | — | 10.1 ± 1.0 | 1.0 |
+ Roflumilast | 7 | −7.21 ± 0.30 | 20.7 ± 2.8* | 2.0 |
+ Formoterol | 7 | −10.45 ± 0.05 | 31.7 ± 0.8*,† | 3.1 |
↵* P < 0.05, Emax of FP response significantly augmented; †P < 0.05, Emax of formoterol response significantly greater than Emax of cilomilast and roflumilast responses.